Baxter buys Oncaspar portfolio from Sigma-Tau for $900mm
Baxter International Inc. paid $900mm cash to buy the Oncaspar (pegaspargase) portfolio from Sigma-Tau Finanziaria SPA. Baxter’s Baxter BioScience division (soon to become the independent publicly traded Baxalta Inc.) will hold rights to the products.
- Large Molecule
- Product Purchase
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com